DBP International AB: US patent for Temodex / SI-053 is granted
Double Bond Pharmaceutical International AB (publ) ("DBP" or "The Company", org. No. 556991-6082) has today, October 05, 2020, received information on granting a US patent application concerning the company's front-line product Temodex / SI-053. Patent approval provides protection for the technology and the product in USA at least until 2036. "This is a very important milestone in the development of SI-053 as USA is the most important market where we plan to expand the global commercialization of the product," comments Igor Lokot, CEO of DBP. - We also have other applications pending